

REVIEW

Open Access

# Mesenchymal stem cell-educated macrophages

Elke Eggenhofer<sup>1\*</sup> and Martin J Hoogduijn<sup>2</sup>

## Abstract

Mesenchymal stem cells (MSC) mediate their immunosuppressive effects via a variety of mechanisms. One of these mechanisms involves the induction of macrophages with immunomodulatory capacities. This effect of MSC may be exploited when MSC are used as a cell therapeutic product. Furthermore, MSC are resident in tissues where they may locally target infiltrating macrophages to adapt more regulatory properties. The present review discusses the interaction between MSC and macrophages, the induction of MSC-educated macrophages, how these cells position between other immune regulatory cells, and how they may be used in the clinic.

## Introduction

Mesenchymal stem cells (MSC) are stromal cells with potent regenerative and immunomodulatory properties [1,2]. They are found in multiple tissues, including bone marrow and adipose tissue [3] and are relatively easy to isolate and expand in culture. Their capacity to differentiate into multiple cellular lineages and their trophic effects on other progenitor cells has initiated interest in the use of these cells for regenerative therapy [4-6]. However, analysis of the mechanisms involved in the reparative effects of MSC indicates that many of these effects may in fact relate to the immunomodulatory properties of MSC. It has been demonstrated that MSC ameliorate acute graft *vs.* host disease [7,8], reduce the progression of kidney fibrosis by modulation of the early inflammatory response after injury [9,10], and in experimental models show promise as a therapeutic treatment of immunological diseases including arthritis [11], hepatitis [12], and organ transplantation [13,14].

MSC have the capacity to modulate the immune system via a plethora of mechanisms. They secrete anti-inflammatory factors such as TGF- $\beta$  and hepatocyte growth factor [2], they inhibit lymphocyte proliferation via the expression of indoleamine 2, 3-dioxygenase (IDO) [15], and they express inhibitory co-stimulatory molecules such as programmed death ligand 1 (PD-L1) and TNF-related apoptosis-inducing ligand (TRAIL) [16,17]. In addition, MSC modulate the immune system via indirect mechanisms by inducing immune cells to

adapt a regulatory function. MSC induce regulatory T cells *in vitro* and *in vivo* [14,18] and affect the differentiation and function of dendritic cells [19]. In recent years it has become clear that MSC also regulate the function of macrophages. Co-culture with MSC induces macrophages to adapt an enhanced regulatory phenotype via expression of increased levels of IL-10, reduced levels of TNF- $\alpha$  and IL-12, low co-stimulatory molecule CD86 and HLA class II while showing higher phagocytic activity [20,21]. This effect of MSC is at least partially mediated by soluble mechanisms and prostaglandin E2 (PGE-2) has been indicated to be one of the factors involved [21].

The question is whether the *in vitro* effects of MSC on macrophages are operational *in vivo*. There is evidence that MSC infusion leads to increased levels of regulatory type monocytes/macrophages in the circulation [22]. This effect is accompanied by an increase in the abundance of regulatory macrophages present within inflamed tissue [22]. Furthermore, it has been shown that locally administered MSC attract macrophages and turn them into a regulatory phenotype [21,23]. Thus *in vivo* administered MSC appear to have a similar effect on macrophages as their *in vitro* counterparts. The mechanisms involved, however, may be very different. There is accumulating evidence that, after administration, MSC are short-lived (Eggenhofer *et al.*, in press). As transiently present MSC may themselves be incapable of secreting sufficient regulatory macrophages inducing factors, additional mechanisms may be important. Indeed, it has been demonstrated that the phagocytosis of dead MSC by macrophages induces them to adapt a more regenerative and immunomodulatory function [24]. This

\* Correspondence: elke.eggenhofer@ukr.de

<sup>1</sup>Department of Surgery, University Medical Center of Regensburg, Franz-Josef-Strauss Allee 11, Regensburg, Germany  
Full list of author information is available at the end of the article

indicates that administered MSC may modulate macrophages function through initiating phagocytosis, while resident MSC that are around for a much longer period of time may modulate macrophages via the secretion of immunomodulatory factors and expression of cell surface molecules. In this respect it is interesting that throughout all tissues MSC are virtually ubiquitous. Tissue-resident MSC have the full capacity to locally induce regulatory macrophages. Studies into the influence of MSC on macrophages behavior are therefore relevant to assessments of MSC as a cell therapeutic product and also to examine the potentially exploitable effects of tissue-resident MSC.

#### **Generation of MSC-educated macrophages (MSC-Mo)**

In the past, research to the immunomodulatory effect of MSC focused on the interactions of MSC with T-lymphocytes, B-lymphocytes, NK cells, and dendritic cells, but recently the effect of MSC on the cells of monocytic lineages, specifically macrophages, has attracted increasing attention. It is well known that MSC can generate an immunoregulatory type of macrophages *in vivo* [23]. Furthermore, it has been shown that MSC can also induce a regulatory macrophage population *in vitro* [20,21].

Recent studies have demonstrated the potential of MSC to educate macrophages to adapt an anti-inflammatory/immune suppressive phenotype. A number of studies allowed direct contact between MSC and macrophages *in vitro* [20,21]. However, other experiments have indicated that MSC can modulate macrophages via soluble factors in a transwell system [20].

After co-culturing with MSC, peripheral blood monocytes derived macrophages (Mo) can be described as a novel type of alternatively activated macrophages (MSC-Mo) [20]. These MSC-Mo remain adherent to plastic and keep a Mo morphology. However, an increased number of Mo can be observed due to the trophic factors secreted by MSC (Figure 1A). They express higher levels of CD206, which is known to be a marker of alternatively activated macrophages and found on other types of anti-inflammatory macrophages as well [25]. Functionally, MSC-Mo display higher phagocytic activity compared to Mo. Moreover, these cells show increased production of anti-inflammatory IL-10 and IL-6, while their production of pro-inflammatory cytokines like IL-12 and TNF $\alpha$  is decreased (Figure 1B). Typically, alternatively activated macrophages are known to promote Th2 type of responses and secrete less pro-inflammatory cytokines (P. Riquelme: The ONE Study workshop 2012). However, these macrophages retain high levels of inflammatory cytokine production, such as TNF- $\alpha$  and IL-6 [26]. Based on those findings, MSC-Mo (IL-10<sup>high</sup>, IL-12<sup>low</sup>, IL-6<sup>high</sup>, and TNF- $\alpha$ <sup>low</sup>) are defined as a

novel type of alternatively activated population of macrophages distinct from previously reported macrophages [20].


#### **Application of MSC-Mo in the clinic**

To date, MSC from adipose tissue or bone-marrow are used in several clinical trials in the treatment of a variety of clinical conditions such as graft *vs.* host disease [7,8], myocardial infarction [27], ischemic stroke [28], Crohn's disease [29,30], diabetes mellitus [31], and acute graft rejection in organ transplantation [32,33]. These ostensibly dissimilar clinical conditions share the role of inflammation in their pathogenesis. Macrophages play a crucial role in not only the initiation but also the continuation of inflammatory processes. To activate macrophages in an alternative way by MSC may reduce inflammation and could modulate immune responses, which is of great therapeutic interest. Many groups and regulatory agencies favor the use of autologous cell therapy to avoid immune recognition. However, isolation, cultivation, and expansion of MSC to a clinical relevant dose normally can require several weeks and is not compatible with the treatment schedules of many conditions, particularly in the case of organ transplantation. Generation of MSC-Mo could be achieved by collection of monocytes through leukapheresis, followed by co-cultivation with a universal source of third party MSCs. Using this strategy a sufficient amount of autologous MSC-Mo could be prepared within a few days in a simple and clinical feasible fashion.

However, (pre-)clinical proof of concept studies with MSC-Mo have yet to be conducted and many questions remain concerning dosage and timing especially in the context of solid organ transplantation. Furthermore, a broader understanding of the potential role of MSC *in situ* and their influence on the generation of MSC-Mo could lead to the development of therapy whereby MSC are used as inducers of regulatory Mo *in vivo*. MSC reside in almost all tissue and will encounter infiltrating Mo in case of inflammation (Figure 2). MSC may thus locally affect the function of Mo and be capable of modulating immune responses in tissues. New therapies may therefore be designed that target tissue MSC to become activated (for example, mimicking local inflammation to create pro-inflammatory microenvironment by injection of pro-inflammatory cytokines) in order to stimulate infiltrating Mo to adapt a regulatory phenotype and function.


#### **Positioning of MSC-Mo between immune regulatory cells**

MSC-Mo belong to a class of myeloid-derived suppressor cells. These cells share a myeloid origin and immune regulatory capacity, but are otherwise a heterogeneous population of cells. They are induced from immature



myeloid cells by factors that are produced during acute or chronic tissue injury or disease [34]. One of these factors, PGE-2, induces myeloid-derived suppressor cells from dendritic cells [35] ([36] N. Obermayer: The ONE Study workshop 2012). Similarly, PGE-2 plays a role in

the induction of MSC-Mo [21]. The production of PGE-2 by MSC increases under inflammatory conditions [37], suggesting an increased efficacy of MSC to induce regulatory Mo under conditions of injury. IL-10 is another factor associated with the generation of myeloid



suppressor cells. It is a potent inducer of tolerogenic IL-10 producing dendritic cells [38], but it is doubtful whether it is involved in the induction of MSC-Mo. There is controversy whether MSC secrete IL-10 but in our hands levels of IL-10 secreted by MSC are neglectable [39]. Furthermore, IFN- $\gamma$ , crucial for the formation of regulatory Mo [40] ([41] P. Riquelme and J. Hutchinson: The ONE Study workshop 2012), does not seem to be involved in the generation of MSC-Mo as MSC hardly secrete this cytokine [39,42]. MSC do secrete, however, a diversity of other factors of which several may play a role in the induction of MSC-Mo.

Functionally, MSC-Mo resemble several other types of myeloid-derived suppressor cells in some respects. Most of these cell types secrete IL-10 while their expression of pro-inflammatory cytokines like IL-6, TNF- $\alpha$ , and IL-12 is reduced. The expression profile of adhesion molecules and the migratory properties of MSC-Mo are not yet elucidated, however. MSC-Mo may differ considerably from non-adherent myeloid-derived suppressor cells in this respect ([43] C. Macedo: The ONE Study workshop 2012). *In vivo*, MSC-Mo are formed in tissues they have infiltrated and where they are exposed to a cocktail of cytokines provided by the stroma. Several types of myeloid-derived suppressor cells that are induced by a single or a small panel of cytokines may therefore come together in the MSC-Mo. Better characterization of the secretory profile of the stroma and the migration patterns of macrophages after encounter with the stroma will reveal more details on these interesting and potentially clinically useful cells.

## Conclusions

MSC provide macrophages with signals that stimulate conversion to a regulatory phenotype. There are two conceivable applications for the generation of MSC-Mo, the first by inducing MSC-Mo through MSC therapy, and the second by the induction of MSC-Mo by tissue-resident MSC. Pre-clinical and clinical studies that aim to use or target MSC in organ transplantation should consider that MSC-Mo may have a vital role in mediating the effects of MSC.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

EE and MJH wrote the manuscript. Both authors read and approved the final manuscript.

## Acknowledgements

This MSC-Mo review is part of a review series resulting from 'The ONE study workshop 2012 - suppressor APC cell therapy', supported by the European Commission (EU FP7-HEALTH 'The ONE Study', Project reference 260687 (11/2010-10/2015)) and generously organized by Professor Geissler and Dr Hutchinson, Regensburg. The authors thank Dr Christian Johnson for proofreading the manuscript.

## Author details

<sup>1</sup>Department of Surgery, University Medical Center of Regensburg, Franz-Josef-Strauss Allee 11, Regensburg, Germany. <sup>2</sup>Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.

Received: 26 April 2012 Accepted: 21 June 2012

Published: 28 September 2012

## References

1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: **Multilineage potential of adult human mesenchymal stem cells.** *Science* 1999, **284**:143–147.
2. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM: **Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.** *Blood* 2002, **99**:3838–3843.
3. da Silva Meirelles L, Chagastelles PC, Nardi NB: **Mesenchymal stem cells reside in virtually all post-natal organs and tissues.** *J Cell Sci* 2006, **119**:2204–2213.
4. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK: **Transplantation and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta.** *Nat Med* 1999, **5**:309–313.
5. Williams AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D, Mendizabal AM, Pattany PM, Lopera GA, Fishman J, Zambrano JP, Heldman AW, Hare JM: **Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling.** *Circ Res* 2011, **108**:792–796.
6. Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, Cattaneo S, Durand DJ, Fitton T, Kuang JQ, Stewart G, Lehrke S, Baumgartner WW, Martin BJ, Heldman AW, Hare JM: **Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction.** *Proc Natl Acad Sci U S A* 2005, **102**:11474–11479.
7. Le Blanc K, Rasmussen I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O: **Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.** *Lancet* 2004, **363**:1439–1441.
8. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O, Developmental Committee of the European Group for Blood and Marrow Transplantation: **Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.** *Lancet* 2008, **371**:1579–1586.
9. Donizetti-Oliveira C, Semedo P, Burgos-Silva M, Cenedeze MA, Malheiros DM, Reis MA, Pacheco-Silva A, Camara NO: **Adipose tissue-derived stem cell treatment prevents renal disease progression.** *Cell Transplant* 2012 Feb 2, Epub ahead of print.
10. Semedo P, Palasio CG, Oliveira CD, Feitoza CQ, Goncalves GM, Cenedeze MA, Wang PM, Teixeira VP, Reis MA, Pacheco-Silva A, Camara NO: **Early modulation of inflammation by mesenchymal stem cell after acute kidney injury.** *Int Immunopharmacol* 2009, **9**:677–682.
11. Bouffi C, Bony C, Courties G, Jorgensen C, Noel D: **IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis.** *PLoS One* 2010, **5**:e14247.
12. Kubo N, Narumi S, Kijima H, Mizukami H, Yagihashi S, Hakamada K, Nakane A: **Efficacy of adipose tissue-derived mesenchymal stem cells for fulminant hepatitis in mice induced by concanavalin A.** *J Gastroenterol Hepatol* 2012, **27**:165–172.
13. Popp FC, Eggenhofer E, Renner P, Slowik P, Lang SA, Kaspar H, Geissler EK, Piso P, Schlitt HJ, Dahlke MH: **Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate.** *Transpl Immunol* 2008, **20**:55–60.
14. Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W, Bartholomew A, Garcia B, Wang H: **Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance.** *Am J Transplant* 2009, **9**:1760–1772.
15. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D: **Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.** *Blood* 2004, **103**:4619–4621.



16. Crop MJ, Baan CC, Korevaar SS, IJzermans JN, Pescatori M, Stubbs AP, van Ijcken WF, Dahlke MH, Eggenhofer E, Weimar W, Hoogduijn MJ: **Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells.** *Clin Exp Immunol* 2010, **162**:474–486.
17. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, Pennesi G: **Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway.** *Eur J Immunol* 2005, **35**:1482–1490.
18. Aggarwal S, Pittenger MF: **Human mesenchymal stem cells modulate allogeneic immune cell responses.** *Blood* 2005, **105**:1815–1822.
19. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE: **Mesenchymal stem cells inhibit generation and function of both CD34+–derived and monocyte-derived dendritic cells.** *J Immunol* 2006, **177**:2080–2087.
20. Kim J, Hematti P: **Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages.** *Exp Hematol* 2009, **37**:1445–1453.
21. Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzon IM, Nepomnaschy I, Costa H, Canones C, Raiden S, Vermeulen M, Geffner JR: **Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile.** *PLoS One* 2010, **5**:e9252.
22. Dayan V, Yannarelli G, Billia F, Filomeno P, Wang XH, Davies JE, Keating A: **Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction.** *Basic Res Cardiol* 2011, **106**:1299–1310.
23. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA, Mezey E: **Bone marrow stromal cells attenuate sepsis via prostaglandin E<sub>2</sub>-dependent reprogramming of host macrophages to increase their interleukin-10 production.** *Nat Med* 2009, **15**:42–49.
24. Lu W, Fu C, Song L, Yao Y, Zhang X, Chen Z, Li Y, Ma G, Shen C: **Exposure to supernatants of macrophages that phagocytized dead mesenchymal stem cells improves hypoxic cardiomyocytes survival.** *Int J Cardiol* 2012 April 2, Epub ahead of print.
25. Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N, Dormont D, Gras G: **Macrophage activation switching: an asset for the resolution of inflammation.** *Clin Exp Immunol* 2005, **142**:481–489.
26. Mosser DM: **The many faces of macrophage activation.** *J Leukoc Biol* 2003, **73**:209–212.
27. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP: **Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction.** *Am J Cardiol* 2004, **94**:92–95.
28. Bang OY, Lee JS, Lee PH, Lee G: **Autologous mesenchymal stem cell transplantation in stroke patients.** *Ann Neurol* 2005, **57**:874–882.
29. Taupin P: **OTI-010 Osiris Therapeutics/JCR Pharmaceuticals.** *Curr Opin Investig Drugs* 2006, **7**:473–481.
30. Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, Kooy-Winkelaar EM, Koning F, Zwaginga JJ, Fidler HH, Verhaar AP, Fibbe WE, van den Brink GR, Hommes DW: **Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.** *Gut* 2010, **59**:1662–1669.
31. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH: **Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes.** *Diabetes* 2008, **57**:1759–1767.
32. Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA, Capelli C, Rambaldi A, Cassis P, Rizzo P, Cortinovis M, Marasa M, Golay J, Noris M: **Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility.** *Clin J Am Soc Nephrol* 2011, **6**:412–422.
33. Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S, Sun X, Chen J, Yang S, Cai J, Gao X, Pileggi A, Ricordi C: **Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.** *JAMA* 2012, **307**:1169–1177.
34. Gabrilovich DI, Nagaraj S: **Myeloid-derived suppressor cells as regulators of the immune system.** *Nat Rev Immunol* 2009, **9**:162–174.
35. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P: **Positive feedback between PGE<sub>2</sub> and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.** *Blood* 2011, **118**:5498–5505.
36. Obermajer N, Kalinski P: **Generation of myeloid-derived suppressor cells using prostaglandin E<sub>2</sub>.** *Transplant Res* 2012, **1**:15.
37. Hoogduijn MJ, Popp F, Verbeek R, Masoodi M, Nicolaou A, Baan C, Dahlke MH: **The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy.** *Int Immunopharmacol* 2010, **10**:1496–1500.
38. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, Hauben E, Roncarolo MG: **Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway.** *Blood* 2010, **116**:935–944.
39. Engela AU, Baan CC, Peeters AM, Weimar W, Hoogduijn MJ: **Interaction between adipose-tissue derived mesenchymal stem cells and regulatory T cells.** *Cell Transplant* 2012 Apr 2, Epub ahead of print.
40. Hutchinson JA, Riquelme P, Geissler EK, Fandrich F: **Human regulatory macrophages.** *Methods Mol Biol* 2011, **677**:181–192.
41. Riquelme P, Geissler EK, Hutchinson JA: **Alternative Approaches to Myeloid Suppressor Cell Therapy in Transplantation: Comparing Regulatory Macrophages to Tolerogenic DCs and MDSCs.** *Transplant Res* 2012, **1**:17.
42. Oh JY, Kim MK, Shin MS, Wee WR, Lee JH: **Cytokine secretion by human mesenchymal stem cells cocultured with damaged corneal epithelial cells.** *Cytokine* 2009, **46**:100–103.
43. Macedo C, Turquist H, Metes D, Thomson AW: **Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation.** *Transplant Res* 2012, **1**:16.

doi:10.1186/2047-1440-1-12

Cite this article as: Eggenhofer and Hoogduijn: Mesenchymal stem cell-educated macrophages. *Transplantation Research* 2012 1:12.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

